# Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis

> **NCT00404820** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 604 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Zoledronic acid 5 mg solution
- **DRUG:** Alendronate 70 mg tablets
- **DRUG:** Calcium/Vitamin D

## Key facts

- **NCT ID:** NCT00404820
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2011-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404820, "Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00404820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*